



## BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025 at 10:05 AM EDT

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- **BioAtla, Inc. (Nasdaq: BCAB)**, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held online and at the McCormick Place Convention Center in Chicago, Illinois from May 30–June 3, 2025.

### **Presentation Details:**

**Title:** Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck

**Abstract Number:** 6048

**Session Type:** Poster #456

**Session Title:** Head and Neck Cancer

**Session Date and Time:** Monday, June 2, 2025; 9:00 AM – 12:00 PM CDT

A copy of the presentation materials can be accessed on the "[Publication](#)" section of the Company's website at [www.bioatla.com](http://www.bioatla.com) once the presentation has concluded.

### **About BioAtla<sup>®</sup>, Inc.**

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla's first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. The Company also has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit [www.bioatla.com](http://www.bioatla.com).

### **Internal Contact:**

Richard Waldron  
Chief Financial Officer  
BioAtla, Inc.  
[rwaldron@bioatla.com](mailto:rwaldron@bioatla.com)  
858.356.8945

### **External Contact:**

Bruce Mackle  
LifeSci Advisors, LLC  
[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)